ChemoCentryx, Inc. (CCXI) News
Filter CCXI News Items
CCXI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CCXI News Highlights
- For CCXI, its 30 day story count is now at 6.
- Over the past 19 days, the trend for CCXI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ENTA, SAIA and VIEW are the most mentioned tickers in articles about CCXI.
Latest CCXI News From Around the Web
Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536- |
ChemoCentryx (CCXI) Receives a Buy from H.C. WainwrightIn a report released today, Edward White from H.C. Wainwright maintained a Buy rating on ChemoCentryx (CCXI – Research Report), with a price target of $101.00. The company's shares closed last Tuesday at $31.51. According to TipRanks.com, White 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics. ChemoCentryx has an analyst consensus of Strong Buy, with a price target consensus of $62.75, implying a 101.9% upside from current levels. |
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceSAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time. |
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesEnanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ...Investment company Lisanti Capital Growth, LLC (Current Portfolio) buys Saia Inc, Knight-Swift Transportation Holdings Inc, Cytokinetics Inc, ArcBest Corp, Inspire Medical Systems Inc, sells CommVault Systems Inc, Varonis Systems Inc, Sprout Social Inc, Acadia Healthcare Co Inc, Crocs Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Lisanti Capital Growth, LLC. |
ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA VasculitisFollowing approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022. |
ChemoCentryx (CCXI) Received its Third Buy in a RowAfter Stifel Nicolaus and Leerink Partners gave ChemoCentryx (NASDAQ: CCXI) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Edward White maintained a Buy rating on ChemoCentryx today and set a price target of $101.00. The company's shares closed last Wednesday at $32.73. According to TipRanks.com, White is a 2-star analyst with an average return of 1.3% and a 32.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Currently, the analyst consensus on ChemoCentryx is a Strong Buy with an average price target of $72.20, a 135.2% upside from current levels. |
Why ChemoCentryx Shares Are RisingChemoCentryx Inc (NASDAQ: CCXI ) shares are Full story available on Benzinga.com |
ChemoCentryx''s Avacopan Scores European Approval For ANCA-Associated VasculitisThe European Union has approved ChemoCentryx Inc''s (NASDAQ: CCXI ) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021 . The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis Full story available on Benzinga.com |
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated VasculitisThe European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021. The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. Related: EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Diso |